5G-EMERALD: Amivantamab in Malignant Brain Tumours

NCT06632236 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Malignant Primary Gliomas
Glioblastoma Multiform (Grade IV Astrocytoma)
Diffuse Hemispheric Glioma, H3 G34-Mutant
Glioblastoma Multiforme (GBM)

Interventions

DRUG: Amivantamab

Sponsor

Institute of Cancer Research, United Kingdom

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]